There are total of 19,456 HIV/AIDS patients received free ARV drugs to date in 159 regions and 441 towns. Current challenges are how to follow-up and evaluate those patients in the clinical settings.

In order to meet the biological constraints, In this paper we consider a system of four equations which captures T-cell-HIV interactions. It describes the behavior of normal T cells, latently-infected ...

With approximately 37 million people living with HIV worldwide and an estimated 2 million new infections reported each year, the need to derive novel strategies aimed at eradicating HIV-1 infection ...

Elton John is ringing the alarm bell on what he views as a potentially dangerous cut to HIV care in the proposed federal budget.

In a historic leap forward for HIV research, scientists have successfully deleted the HIV genome from living human immune cells and, in a separate advance, exposed hidden reservoirs of the virus using ...

HIV-1 integrase (IN) is an enzyme which is indispensable for the stable infection of host cells because it catalyzes the insertion of viral DNA into the genome and thus is an attractive target for the ...

The Food and Drug Administration (FDA) has approved Yeztugo (aka. lenacapavir or LEN), a twice-a-year injection that stops HIV from replicating inside cells, thereby reducing the risk of ...

According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African participants who bear the highest burden of HIV-1.

Antiretroviral therapy initiated during acute infection in women with HIV-1 clade C reduces anti-Tat antibody production and lowers CD8+ T cell activation ...

Transplantation of human hematopoietic stem cells engineered to lack the viral coreceptor CCR5 confers resistance to HIV infection in mice.

During cell-to-cell spread, HIV-1 protease activity triggers CARD8 inflammasome activation and IL-1β release from macrophages, which may contribute to inflammation and chronic immune activation.